Nixon, Andrew B.
Liu, Yingmiao
Yang, Qian
Luo, Bin
Starr, Mark D.
Brady, John C.
Kelly, Wm Kevin
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
Morris, Michael J. http://orcid.org/0000-0002-9454-0096
George, Daniel J. http://orcid.org/0000-0002-0836-8542
Armstrong, Andrew J. http://orcid.org/0000-0001-7012-1754
Halabi, Susan http://orcid.org/0000-0003-4135-2777
Funding for this research was provided by:
United States Department of Defense | U.S. Army (W81XWH-18-1-0278, W81XWH-18-1-0278, W81XWH-18-1-0278)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10CA180821, U10CA180822, U24CA196171)
Prostate Cancer Foundation
Article History
Received: 4 August 2023
Accepted: 16 January 2024
First Online: 12 February 2024
Competing interests
: A.B. Nixon has received research funding from Genentech, HTG Molecular Diagnostics, MedImmune/AstraZeneca, Medpacto, Promega Corporation, Seattle Genetics; and has received consultant/advisory compensation from AdjuVolt Therapeutics, Eli Lilly, GSK, Leap Therapeutics, Promega Corporation. D.J. George has received consultant/advisory compensation from Astellas, Astrazeneca, Axess Oncology, Bayer H/C Pharmaceuticals, BMS, Capio Biosciences, Constellation Pharmaceuticals, EMD Serono, Exelixis Inc., Flatiron, Ipsen, Janssen Pharmaceuticals, Merck Sharp & Dohme, Michael J Hennessey Associates, Modra Pharmaceuticals B. V., Myovant Sciences, Nektar Therapeutics, Physician Education Resource LLC, Pfizer, Propella TX, RevHealth LLC, Sanofi, UroGPO; and has received research funding from Astrazeneca, BMS, Calithera, Exelixis Inc., Janssen Pharmaceuticals, Novartis, Pfizer, Sanofi. H. Beltran has served as consultant/advisory board member for Janssen, Sanofi Genzyme, Astellas, Astra Zeneca, Merck, Pfizer, Foundation Medicine, Blue Earth Diagnostics, Amgen, Oncorus and has received research funding (to institution) from Janssen Oncology, AbbVie/Stemcentrx, Eli Lilly, Millennium Pharmaceuticals, Bristol Myers Squibb. A.J. Armstrong is a paid consultant with Pfizer, Astellas, Forma, BMS, Janssen, Bayer, Astrazeneca, Novartis, and Merck and receives research funding (to his institution) from Pfizer, Astellas, Janssen, Bayer, Dendreon, Novartis, Genentech/Roche, Merck, BMS, Astrazeneca, Constellation, Beigene, Forma, and Amgen. S. Halabi was on the DMC for Aveo, BMS, Janssen and Sanofi and receives research funding from Astellas and ASCO (Institution). The other authors declare no potential conflicts of interest.